Thank you for donating!

You can donate using the following services.

News

  1. 05.10.17

    Update #17 on the AIDNPC Clinical Programme

    The study was recently completed in May 2017. A total of 35 patients were enrolled across 12 sites in 8 countries. The primary objective of the 001 study was to characterize the individual patient’s disease progression profile through clinical, biological and quality-of-life measures recorded prospectively, as well as the historic disease information collected from patient medical records. The 001 study has already provided us with some valuable learnings: The NPC-CSS disease score were completed by patients with a good compliance, the skin biopsies and blood tests have been valuable for development and conformation of biomarkers, and we found that two-thirds of patients were treated with miglustat as part of their standard of care. Once all data have been analysed, we expect to gain insight about biomarkers and how the disease evolves over time in greater detail.

    Read more
  2. 20.09.17

    Route of Administration Preferences Study

    There is an opportunity for you to participate in a market research study about Niemann-Pick Type C, conducted by an organization called ApotheCom on behalf of an industry sponsor.

    The goal of the study is to understand your preferences and concerns regarding the method through which a drug could be administered to manage Niemann-Pick Type C.

    Read more
  3. 20.09.17

    NP-C Patient Flow Study 2017

    We are pleased to inform you about an opportunity to share your story of living with Niemann-Pick Type C (NPC) in a market research study.

    An independent market research organisation, Magnolia Innovation, is currently conducting research with people, or parents of children, who have NP-C.

    The goal of the research is to understand the challenges of diagnosis, care and everyday activities of living with NPC. Magnolia would be very grateful to hear your stories and experiences in a one-hour phone interview to understand more about this condition.

    Read more
  4. 18.09.17

    NPUK Annual Family Conference & Interactive Workshop 2017 (Preliminary Programme)

    The preliminary programme for this year's Annual Family Conference & Interactive Workshop is finally here - we are excited to once again welcome our community to the biggest event in the NPUK calendar!

    Read more
  5. 07.09.17

    IntraBio announces plans for a multi-national randomised clinical trial to evaluate IB1000 as a therapeutic intervention for patients with NP-C

    IntraBio announces plans for a multi-national randomised clinical trial to evaluate IB1000 as a therapeutic intervention for patients with NP-C...

    Read more